Cholinergic neuron impairment is a significant cause of cognitive decline in Alzheimer’s disease (AD), making acetylcholinesterase (AChE) a key therapeutic target. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.